Exploration of different immunotherapy modalities in osteosarcoma
骨肉瘤不同免疫治疗方式的探索
基本信息
- 批准号:10730833
- 负责人:
- 金额:$ 44.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-05 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:Adaptive Immune SystemAdenovirus VectorAdultAdverse effectsAffectAntigen PresentationBindingBiological AssayBystander EffectCAR T cell therapyCAV2 geneCD276 geneCanis familiarisCell DeathCell LineCellsChildChildhood OsteosarcomaCombined Modality TherapyCytolysisDevelopmentDiseaseDisease-Free SurvivalDistantDown-RegulationEnvironmentGenerationsGoalsImmune checkpoint inhibitorImmune responseImmune systemImmunityImmunologic StimulationImmunotherapyIndividualInfiltrationInflammatory ResponseLaboratoriesMalignant Bone NeoplasmMalignant NeoplasmsMeasurementMediatingMembrane ProteinsModalityModelingMolecularMonoclonal AntibodiesOncolytic virusesOperative Surgical ProceduresPD-1 inhibitorsPD-1/PD-L1PDL1 inhibitorsPatientsPatternProductionProteinsRecombinantsSiteSurface AntigensSurvival RateT-LymphocyteTestingTransgenesTranslationsTumor AntigensTumor ImmunityUnited StatesVirotherapyanti-PD-1anti-PD-L1anti-PD1 antibodiesarmbonecancer cellcancer geneticscancer immunotherapeuticscancer immunotherapycancer therapycell killingchemokinechemotherapychimeric antigen receptor T cellscombatconditionally replicative adenoviruscytokinecytotoxicdesigneffector T cellimmune checkpointinterdisciplinary treatment approachlong bonemultimodalitynanobodiesneoantigensneoplastic cellnovelnovel strategiesoncolytic adenovirusoncolytic virotherapyosteosarcomaprogrammed cell death ligand 1programmed cell death protein 1receptorresponseskillssynergismtargeted treatmentthree dimensional cell culturetransmission processtumortumor eradicationtumor initiationtumor microenvironmenttumor-immune system interactionsvector
项目摘要
Project Summary/Abstract
Osteosarcoma (OS) is the most common primary bone malignancy affecting long bones in children and the third
most frequent in adults in the United States. The survival rates over the last 20 years are unchanged. OS is also
the most common malignant bone tumor (80%) in dogs. Treatment options for OS are limited. Immunotherapy
is a promising new approach that has yet to be fully explored in OS. Chimeric antigen receptor (CAR) T cells are
designed to express recombinant receptors to target specific tumor cell surface antigens and promote T cell-
mediated cancer cell death. However, one of the biggest challenges in CAR T cell therapy is the
immunosuppressive tumor micro-environment (TME). Another immunotherapy strategy is the use of immune
checkpoint inhibitors, such as monoclonal antibodies (mAb) against PD-1. Anti-PD-1 mAbs have shown
significant efficiency in treating multiple tumors but cause adverse effects due to systemic delivery of the mAb.
To avoid systemic delivery, oncolytic viruses can be designed to produce immune checkpoint inhibitors directly
in TME to boost the immune system and enable T cells to kill tumor cells. Conditionally replicative adenoviruses
(CRAds) replicate only in tumor cells, lyse them, and stimulate anti-tumor immunity in TME and at distant sites
of disease, causing a bystander effect. However, the limited number of effector T cells against cancer antigens
limits the efficacy of this approach. Therefore, we propose a combination therapy to synergize these strategies
to combat tumor cells. We will combine CAR T cell therapy, oncolytic virus, and PD-1/PD-L1 inhibitor to target
osteosarcoma tumor cells. We have developed an armed oncolytic adenovirus to produce anti-PD-1 Ab in the
TME. We will create two more armed oncolytic viruses that will produce secreted single domain antibodies (sdAb)
to PD1 and PDL1. We will evaluate CRAd and CAR T cell (against B7-H3) induced tumor cells lysis. The
conditionally replicated oncolytic viruses will produce anti-PD1 and anti-PDL1 sdAb in TME, reducing the adverse
effects of systemic administration, and enhancing anti-tumor immunity. CAR T cells against B7-H3 will initiate
tumor cell killing in an activated TME. Ultimately, beyond the scope of this proposal, this approach will be tested
in spontaneous OS in canine patients, before translation to pediatric OS patients.
项目摘要/摘要
骨肉瘤(OS)是影响儿童长骨的最常见的原发骨恶性肿瘤,在儿童中占第三位
在美国,最常见的是成年人。过去20年的存活率没有变化。操作系统也是
狗最常见的恶性骨肿瘤(80%)。OS的治疗选择有限。免疫疗法
是一种很有前途的新方法,还没有在操作系统中得到充分的探索。嵌合抗原受体(CAR)T细胞
旨在表达针对特定肿瘤细胞表面抗原的重组受体,并促进T细胞-
导致癌细胞死亡。然而,CAR T细胞疗法最大的挑战之一是
免疫抑制肿瘤微环境(TME)。另一种免疫治疗策略是使用免疫
检查点抑制物,如抗PD-1的单抗。抗PD-1单抗已显示
在治疗多种肿瘤方面显著有效,但由于全身注射单抗而引起不良反应。
为了避免全身传播,溶瘤病毒可以设计成直接产生免疫检查点抑制物。
在TME中增强免疫系统,使T细胞能够杀死肿瘤细胞。条件性复制型腺病毒
(CRAds)仅在肿瘤细胞中复制、裂解,并在TME和远端部位激发抗肿瘤免疫
引起旁观者效应的疾病。然而,抗癌抗原的效应性T细胞数量有限
限制了此方法的有效性。因此,我们提出了一种联合疗法来协同这些策略。
来对抗肿瘤细胞。我们将结合CAR T细胞治疗、溶瘤病毒和PD-1/PD-L1抑制剂来靶向
骨肉瘤肿瘤细胞。我们已经开发出一种武装的溶瘤腺病毒,在小鼠体内产生抗PD-1抗体。
我也是。我们将再制造两种武装溶瘤病毒,它们将产生分泌型单域抗体(SdAb)。
至PD1和PDL1。我们将评估CRAd和CAR T细胞(抗B7-H3)诱导的肿瘤细胞裂解。这个
有条件复制的溶瘤病毒将在TME中产生抗PD1和抗PDL1 sdAb,从而减少对
全身给药的效果,增强抗肿瘤免疫。针对B7-H3的CAR T细胞将启动
在活化的TME中杀死肿瘤细胞。最终,在本提案的范围之外,将对这种方法进行测试
在犬自发性OS患者中,在移植到儿童OS患者之前。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Payal Agarwal其他文献
Payal Agarwal的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
- 批准号:
19K09482 - 财政年份:2019
- 资助金额:
$ 44.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
- 批准号:
2273599 - 财政年份:2019
- 资助金额:
$ 44.06万 - 项目类别:
Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
- 批准号:
18K14964 - 财政年份:2018
- 资助金额:
$ 44.06万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
- 批准号:
16K18873 - 财政年份:2016
- 资助金额:
$ 44.06万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
- 批准号:
9193681 - 财政年份:2016
- 资助金额:
$ 44.06万 - 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
- 批准号:
15K18939 - 财政年份:2015
- 资助金额:
$ 44.06万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
- 批准号:
26450450 - 财政年份:2014
- 资助金额:
$ 44.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
- 批准号:
26462183 - 财政年份:2014
- 资助金额:
$ 44.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
- 批准号:
26893253 - 财政年份:2014
- 资助金额:
$ 44.06万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
- 批准号:
24701021 - 财政年份:2012
- 资助金额:
$ 44.06万 - 项目类别:
Grant-in-Aid for Young Scientists (B)